Development of the epidermal growth factor receptor inhibitor OSI-774

Seminars in Oncology

Volumn 30, Issue 3 SUPPL. 6, 2003, Pages 23-31

  Grünwald, Viktor ^b   Hidalgo, Manuel ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; PACLITAXEL; TETRACYCLINE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; CONCENTRATION RESPONSE; DIARRHEA; DOSE RESPONSE; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HEAD AND NECK CANCER; HEADACHE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; META ANALYSIS; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RASH; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; VOMITING;

EID: 0037838557     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)70022-0     Document Type: Article

References (17)

1. Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 103:211-225, 2000
2. Yarden Y: The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 37:S3-S8, 2001 (suppl 4)
3. Grunwald V, Hidalgo M: The epidermal growth factor receptor: A new target for anticancer therapy. Curr Probl Cancer 26:109-164, 2002
4. Moyer JD, Barbacci EG, Iwata KK, et al: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57:4838-4848, 1997
5. Pollack VA, Savage DM, Baker DA, et al: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291:739-748, 1999
6. Karp D, Ferrante KJ, Tensfeldt TG, et al: A phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients (pts) with advanced solid tumors. Lung Cancer 29:65, 2000 (suppl 1) (abstr)
7. Hidalgo M, Malik S, Rowinsky E, et al: Inhibition of the epidermal growth factor receptor (EGFR) by OSI-774, a specific EGFR inhibitor in malignant and normal tissues of cancer patients. Proc Am Soc Clin Oncol 20:7a, 2001 (abstr 281)
8. Forouzesh B, Hidalgo M, Takimoto C, et al: Phase I, pharmacokinetic (PK), and biological studies of the epidermal growth factor-tyrosine kinase (EGFR-TK) inhibitor OSI-774 in combination with docetaxel. Proc Am Soc Clin Oncol 21:21a, 2002 (abstr 81)
9. Forero L, Patnaik A, Hammond LA, et al: Phase I, pharmacokinetic (PK) and biologic study of OSI-774, a selective epidermal factor receptor (EGFR) tyrosine kinase (TK) inhibitor in combination with paclitaxel and carboplatin. Proc Am Soc Clin Oncol 21:25b, 2002 (abstr 1908)
10. Ratain MJGC, Janisch L, Kindler HL, et al: Phase I trial of elotinib (OSI-774) in combination with gemcitabine (G) and cisplatin (P) in patients with advanced solid tumors. Proc Am Soc Clin Oncol 21:76b, 2002 (abstr 2115)
11. Finkler F, Gordon A, Crozier M, et al: Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. Proc Am Soc Clin Oncol 20:208a, 2001 (abstr 831)
12. Senzer NN, Soulieres D, Siu L, et al: Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 20:2a, 2001 (abstr 6)
13. Perez-Soler R, Chachoua A, Huberman M, et al: A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20:310a, 2001 (abstr 1235)
14. Bishop PC, Myers T, Robey R, et al: Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Oncogene 21:119-127, 2002
15. Moulder SL, Yakes FM, Muthuswamy SK, et al: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61:8887-8895, 2001
16. Motoyama AB, Hynes NE, Lane HA: The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 62:3151-3158, 2002
17. Malik SN, Brattain M, Ghosh PM, et al: Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8:1168-1171, 2002